Modeling of Production Industrial Process of the Drug Flocalin and Search of its Optimally Effective Dose in Treatment of Heart Diseases
DOI:
https://doi.org/10.15407/scin9.01.055Keywords:
Flocalin, ischemia-reperfusion, cardioprotection, industrial production.Abstract
The possible ways of the industrial production of drug Flocalin in the high-frequency microwave field is determined. Suitable production technology is elaborated. In the experiments with ischemia-reperfusion of myocardium effects of different doses of Flocalin on cardiac hemodynamic and blood biochemical parameters, which represent possible course of cardioprotective processes, were studied in detail. It was shown that Floсalin dose of 1,5-2,2 mg/kg may be considered as optimal effective dose in treatment of heart diseases.
References
Voitychuk O.I., Strutynskyi R.B., Yagupolskii L.M. et al. Sarcolemmal cardiac KATP channels as a target for the cardioprotective effects of the fluorine-containing pinacidil analogue flocalin. Brit J Pharmacol. 2011. V. 162. No. 3. P. 701-711.
https://doi.org/10.1111/j.1476-5381.2010.01072.x
Strutyns'kyj R.B., Pyvovar S.M., Tumanovs'ka L.V., Mojbenko O.O. Kardioprotektorni efekty flokalinu: vidnosna rol' aktyvacii' sarkolemal'nyh ta mitohondrial'nyh adenozyntryfosfatzalezhnyh kalijevyh KATF-kanaliv. Fiz.zhurn. 2008. T. 54, No. 6. S. 15-23 [in Ukrainian].
Mojbenko O.O., Strutyns'kyj R.B., Jagupol's'kyj L.M. ta in. Organizacija zavods'kogo vygotovlennja preparatu Flokalin - novogo vitchyznjanogo miotropnogo spazmolitika i kardioprotektora. Nauka innov. 2009, 5(1):80-84 [in Ukrainian].
https://doi.org/10.15407/scin5.01.080
Voitychuk O.I., Strutynskyi R.B., Shuba Y.M. Effects of ATP-dependen potassium channel activator flocalin include sodium and calcium channels inhibition in cardiomyocytes. The Biophysical Society 55th Annual Meeting in Baltimore, Maryland, March 5-9, 2011.
Mojbenko O.O., Strutins'kij R.B., Jagupol's'kij L.M. ta in. Vozmozhnye mehanizmy kardioprotektornyh jeffektov aktivacii KATF kanalov pri ishemii-reperfuzii miokarda. Bjuleten' XX - chitan' im. V.V. Pidvisockogo, 26-27 travnja 2011 r., Odesa. S. 135-136 [in Russian].
Bhatnagar A., Bolli R. Modulation of KATP channels to protect the ischemic myocardium: Clinical implications. Exp Clin Cardiol. 1999. Vol. 4, No. 1. P. 20-22.
Mojbenko O.O., Strutyns'kyj R.B., Jagupol's'kyj L.M., Mohort M.A. Rozrobka ta pidgotovka do vprovadzhennja novogo vitchyznjanogo kardioprotektornogo preparatu - ftorvmisnogo aktyvatora ATF-zalezhnyh ka lijevyh kanaliv Flokalin. Nauka innov. 2006, 2(4):77-82 [in Ukrainian].
Gorobec' M.Ju., Ostras' K.S., Shalamaj A.S. ta in. Patent Ukrai'ny No. 88756 A 61 K 31/03 (2009.01). Sposib oderzhannja N-(4-Dyftorometoksyfenil)-N’-1,2,2-trymetylpropil-N’’-cianoguanidynu (Flokalinu) No. a 2009 06551; Zajav. 22.06.2009; Opubl. 10.11.2009. Promyslova vlasnist'. 2009. Bjul. No. 21 [in Ukrainian].
Strutyns'kyj R.B., Rovenec' R.A., Neshheret O.P. ta in. Vplyv likars'koi' formy flokalinu na perebig ishemii'-reperfuzii' miokarda. Fiz.zhurn. 2011. T. 57, No. 1. S. 55-65 [in Ukrainian].
Strutyns'kyj R.B. Doslidzhennja vplyvu novyh aktyvatoriv ATF-zalezhnyh kalijevyh kanaliv na funkcii' sercja ta vazomotorni reakcii' v normal'nyh ta patologichnyh umovah. Avtoreferat dysertacii' na poshuk uchenogo stupenja kandydata biologichnyh nauk: 14.03.04. Kyi'v. 2002. 20 s. [in Ukrainian].
Grover G.J., Baird A.J., Sleph P.G. Lack of pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts. Cardiovasc Res. 1996. Vol. 31, No. 4. P. 511-517.
https://doi.org/10.1016/S0008-6363(95)00223-5
Strutyns'kyj R.B., Kocjuruba A.V., Neshheret O.P. ta in. Zminy metabolizmu v miokardi pry ishemii'-reperfuzii' ta aktyvacii' ATF-chutlyvyh kalijevyh kanaliv. Fiz.zhurn. 2012. T. 58, No. 1. S. 13-26 [in Ukrainian].
